Palisade Capital Management’s Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A BSX.PRA Stock Holding History
Bought
Maintained
Sold
Other funds holding BSX.PRA
Palisade Capital Management's BSX.PRA Position: Q2 2023 in Review
Palisade Capital Management sold out of Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A (BSX.PRA) in Q2 2023, closing a stake of 22,150 shares — an estimated $2.67M sold.
Palisade Capital Management first reported a position in BSX.PRA in Q1 2022 and held it in 5 quarters. The position peaked at $4.18M in Q4 2022. 1 fund tracked by Wall St. Rank holds BSX.PRA as of Q2 2023.
- Palisade Capital Management reported no remaining Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position as of Q2 2023 after selling out during the quarter.
- Palisade Capital Management sold 22,150 Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A shares in Q2 2023, an estimated $2.67M.
- Palisade Capital Management first reported a position in Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A in Q1 2022 and held it in 5 quarters.
- Palisade Capital Management's Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A position peaked at $4.18M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A as of Q2 2023.
Based on Palisade Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.